Rasmus Michael Sandsdal (Rasmus M Christensen, Rasmus M Sandsdal)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Cardiovascular Risk Factors

Systematic Review

Top Venues

Obesity reviews : an official journal of the International Association for the Study of Obesity

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjaer Jensen, Signe Sørensen Torekov
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity 25 (5) (2024)
Adrian F Bogh, Simon B K Jensen, Christian R Juhl, Charlotte Janus, Rasmus Michael Sandsdal, Julie R Lundgren, Mikkel H Noer, Nhu Q Vu, Matteo Fiorenza, Bente M Stallknecht, Jens J Holst, Sten Madsbad, Signe Sørensen Torekov
Insufficient sleep predicts poor weight loss maintenance after one year. Sleep (2022)
Simon Birk Kjær Jensen, Charlotte Janus, Julie Rehné Lundgren, Christian Rimer Juhl, Rasmus Michael Sandsdal, Lisa Møller Olsen, Anne Andresen, Signe Amalie Borg, Ida Christine Jacobsen, Graham Finlayson, Bente Merete Stallknecht, Jens Juul Holst, Sten Madsbad, Signe Sørensen Torekov
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nature communications 13 (1) (2022)
Rasmus Michael Sandsdal, Christian R Juhl, Signe Sørensen Torekov
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. Drug safety 42 (8) (2020)